Literature DB >> 31315963

Individualized Prediction of Survival Benefit from Postmastectomy Radiotherapy for Patients with Breast Cancer with One to Three Positive Axillary Lymph Nodes.

Ning Zhang1, Jiashu Zhang1, Hanwen Zhang1, Ying Liu1, Wenjing Zhao2, Lijuan Wang2, Bing Chen2, Meena S Moran3, Bruce G Haffty4, Qifeng Yang5,2.   

Abstract

PURPOSE: There still exist some arguments regarding the use of postmastectomy radiotherapy (PMRT) for patients with breast cancer carrying one to three positive axillary lymph nodes considering the heterogeneity of this cohort. Here, we developed a prognostic nomogram to estimate the probability of long-term outcome in patients receiving or not receiving PMRT in order to assist in making individually locoregional treatment decisions for this particular cohort.
METHODS: Altogether, 20,336 women, aged 18 to 80 years, diagnosed with breast cancer, and carrying one to three positive nodes were identified in the Surveillance, Epidemiology, and End Results (SEER) database. We applied multivariant Cox hazard model to determine the impact of covariates on disease-specific survival (DSS) and overall survival (OS). Then, the nomogram was built accordingly. Internal and external validations were performed to examine the accuracy of nomograms.
RESULTS: Age of diagnosis, tumor grade, size, estrogen and progesterone receptor status, and number of positive nodes were independent factors of DSS and OS in the multivariate analysis. Incorporating these factors into the constructed nomogram showed high accuracy when predicting 5- and 10-year survival, with internally and externally bootstrap-corrected concordance indexes in the range of 0.6 to 0.8.
CONCLUSION: Besides the number of involved nodes, extra variables existed as predictors of survival outcomes in this cohort; therefore, the recommendation of PMRT or no PMRT requires comprehensive consideration. This clinically validated nomogram provided a useful tool that could aid decision making by estimating DSS and OS benefits from PMRT, useful in predicting 5- and 10-year DSS and OS for patients with one to three positive nodes after mastectomy. IMPLICATIONS FOR PRACTICE: This study evaluated population-based data to identify prognostic factors associated with patients with breast cancer with one to three lymph nodes and help clinicians to weigh the benefit of postmastectomy radiotherapy (PMRT). Surveillance, Epidemiology, and End Results (SEER) data were used to develop a prognostic nomogram to predict the likelihood of long-term survival with and without PMRT in order to optimize the individual locoregional control strategy for this particular cohort. This clinically validated nomogram provides a useful tool to predict 5- and 10-year disease-specific survival and overall survival for patients with one to three positive nodes and can aid tailored clinical decision making by estimating predicted benefit from PMRT. © AlphaMed Press 2019.

Entities:  

Keywords:  Axillary lymph nodes; Breast cancer; Postmastectomy radiotherapy; Survival

Year:  2019        PMID: 31315963      PMCID: PMC6975954          DOI: 10.1634/theoncologist.2019-0124

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  32 in total

1.  Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report.

Authors:  P Karlsson; B F Cole; B H Chua; K N Price; J Lindtner; J P Collins; A Kovács; B Thürlimann; D Crivellari; M Castiglione-Gertsch; J F Forbes; R D Gelber; A Goldhirsch; G Gruber
Journal:  Ann Oncol       Date:  2012-07-09       Impact factor: 32.976

2.  Deep-Inspiration Breath-Hold Radiation Therapy in Breast Cancer: A Word of Caution on the Dose to the Axillary Lymph Node Levels.

Authors:  Kai Joachim Borm; Markus Oechsner; Stephanie E Combs; Marciana-Nona Duma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-20       Impact factor: 7.038

Review 3.  Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Authors:  Abram Recht; Elizabeth A Comen; Richard E Fine; Gini F Fleming; Patricia H Hardenbergh; Alice Y Ho; Clifford A Hudis; E Shelley Hwang; Jeffrey J Kirshner; Monica Morrow; Kilian E Salerno; George W Sledge; Lawrence J Solin; Patricia A Spears; Timothy J Whelan; Mark R Somerfield; Stephen B Edge
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

4.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Authors:  M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

5.  Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.

Authors:  Shirin Muhsen; Tracy-Ann Moo; Sujata Patil; Michelle Stempel; Simon Powell; Monica Morrow; Mahmoud El-Tamer
Journal:  Ann Surg Oncol       Date:  2018-03-21       Impact factor: 5.344

6.  Regional Nodal Irradiation in Early-Stage Breast Cancer.

Authors:  Timothy J Whelan; Ivo A Olivotto; Wendy R Parulekar; Ida Ackerman; Boon H Chua; Abdenour Nabid; Katherine A Vallis; Julia R White; Pierre Rousseau; Andre Fortin; Lori J Pierce; Lee Manchul; Susan Chafe; Maureen C Nolan; Peter Craighead; Julie Bowen; David R McCready; Kathleen I Pritchard; Karen Gelmon; Yvonne Murray; Judy-Anne W Chapman; Bingshu E Chen; Mark N Levine
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

7.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

Authors:  Bernard H Bochner; Michael W Kattan; Kinjal C Vora
Journal:  J Clin Oncol       Date:  2006-07-24       Impact factor: 44.544

8.  Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy.

Authors:  Xingxing Chen; Xiaoli Yu; Jiayi Chen; Zhaozhi Yang; Zhimin Shao; Zhen Zhang; Xiaomao Guo; Yan Feng
Journal:  Oncologist       Date:  2013-01-18

9.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

10.  Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.

Authors:  Galina Velikova; Linda Jane Williams; Sarah Willis; J Michael Dixon; Juliette Loncaster; Matthew Hatton; Jacqueline Clarke; Ian H Kunkler; Nicola S Russell
Journal:  Lancet Oncol       Date:  2018-10-15       Impact factor: 41.316

View more
  1 in total

1.  A Prognostic Risk Stratification Model to Identify Potential Population Benefiting From Postmastectomy Radiotherapy in T1-2 Breast Cancer With 1-3 Positive Axillary Lymph Nodes.

Authors:  Niuniu Hou; Juliang Zhang; Lu Yang; Ying Wu; Zhe Wang; Mingkun Zhang; Li Yang; Guangdong Hou; Jianfeng Wu; Yidi Wang; Bingyao Dong; Lili Guo; Mei Shi; Rui Ling
Journal:  Front Oncol       Date:  2021-04-19       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.